First patients to try new pill targeting common cancer mutation
NCT ID NCT07021898
Summary
This is the first study in people to test a new oral drug called ERAS-4001. It aims to find a safe dose and see how the body handles the drug in patients with advanced solid tumors that have specific KRAS mutations. The drug will be tested alone and in combination with other cancer therapies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Fred Hutchinson Cancer Center
RECRUITINGSeattle, Washington, 98109, United States
-
NEXT Oncology
RECRUITINGIrving, Texas, 75039, United States
-
NEXT Oncology
RECRUITINGSan Antonio, Texas, 78229, United States
-
Sarah Cannon Research Institute (SCRI) Oncology Partners
RECRUITINGNashville, Tennessee, 32703, United States
-
The University of Texas MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.